3,499 results match your criteria Prolactinoma


Fertility after transsphenoidal surgery in patients with prolactinomas: A meta-analysis.

Clin Neurol Neurosurg 2018 Dec 1;176:53-60. Epub 2018 Dec 1.

Computational Neuroscience Outcomes Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; School of Pharmacy, MCPHS University, Boston, MA, USA(3). Electronic address:

Pituitary prolactinomas in women often lead to amenorrhea, galactorrhea, or infertility. The purpose of this study was to evaluate the effectiveness of transsphenoidal surgery (TSS) in restoring fertility in women with proloactinomas. A systematic search of the literature was conducted in accordance with PRISMA guidelines through 6/13/2017. Read More

View Article
December 2018

Giant prolactinoma, germline BRCA1 mutation, and depression: a case report.

J Med Case Rep 2018 Dec 6;12(1):360. Epub 2018 Dec 6.

Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São João, E.P.E., Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portugal.

Background: Giant prolactinomas are very rare pituitary tumors that may exhibit an aggressive behavior and present with a life-threatening condition.

Case Presentation: A 25-year-old white woman was admitted to our hospital with a headache, psychomotor retardation, reduced vision, and loss of autonomy in daily activities. Her past medical history was significant for having oligomenorrhea and a depressive syndrome since her mother's death. Read More

View Article
December 2018
3 Reads

Management of dopamine agonist-resistant prolactinoma.

Authors:
Dominique Maiter

Neuroendocrinology 2018 Nov 27. Epub 2018 Nov 27.


Dopamine agonists are usually very effective in the treatment of prolactinomas. Nonetheless, a subset of individuals does not respond satisfactorily to these agents and this resistance is characterized by failure to achieve normoprolactinaemia and a 30% or more reduction in maximal tumor diameter (in the case of macroprolactinoma) under maximally tolerated doses. Its overall prevalence is 20-30% for bromocriptine (BRC) and around 10% for cabergoline (CAB). Read More

View Article
November 2018
2 Reads

Direct Carotid Cavernous Fistula Due to Rupture of a Cavernous Carotid Aneurysm Embedded within a Prolactinoma after Cabergoline Administration.

World Neurosurg 2018 Nov 19. Epub 2018 Nov 19.

Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan.

Background: A small number of reports have discussed subarachnoid hemorrhage from a ruptured aneurysm embedded within a prolactinoma. To the best of our knowledge, however, no reports have discussed an embedded carotid cavernous fistula (CCF). We report a patient with CCF secondary to a ruptured internal carotid artery (ICA) aneurysm embedded within a prolactinoma. Read More

View Article
November 2018
4 Reads

Human Prolactinoma: A View of Protein-Protein Interaction Pattern.

Int J Endocrinol Metab 2018 Oct 6;16(4):e67332. Epub 2018 Aug 6.

Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

The aim of this study was to identify the highly expressed genes in terms of interaction concept in Prolactinoma. The study was conducted by additional analysis of the available data from the GEO database. The online tool, GEO2R, was used to analyze the gene expression profile of GSE36314 dataset using the GPL8300 platform. Read More

View Article
October 2018
1 Read

Screening of AIP Gene Variations in a Cohort of Turkish Patients with Young-Onset Sporadic Hormone-Secreting Pituitary Adenomas.

Genet Test Mol Biomarkers 2018 Nov 21. Epub 2018 Nov 21.

2 Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University , Istanbul, Turkey .

Aims: Aryl hydrocarbon receptor-interacting protein (AIP) gene mutations have long been associated with apparently sporadic pituitary adenomas (PAs) with a prevalence range of 0-12%. The aim of this study was to evaluate the frequency of germline AIP variations in a large cohort of apparently sporadic PAs diagnosed before the age of 40 years, who did not exhibit hypercalcemia and/or MEN1 syndrome components during long-term follow-up.

Materials And Methods: A total of 97 patients, diagnosed with functional PAs ≤40 years old, composed of somatotropinoma (n = 55), prolactinoma (n = 25), and corticotrophinoma (n = 17), were recruited for this study. Read More

View Article
November 2018
6 Reads

Spontaneous preoperative pituitary adenoma resolution following apoplexy: a case presentation and literature review.

Br J Neurosurg 2018 Nov 19:1-6. Epub 2018 Nov 19.

a Department of Neurological Surgery , University of Miami Miller School of Medicine , Miami , FL , USA.

Purpose: We aim to more fully understand the incidence and natural history of spontaneously resolving non-functioning pituitary adenomas (NFPAs).

Methods: We report a case of spontaneous complete resolution of a NFPA revealed by preoperative magnetic resonance imaging. In addition, we searched all major databases and neurosurgery journals to perform a comprehensive literature review of all previously reported cases of spontaneously resolving NFPAs. Read More

View Article
November 2018
1 Read

Association of prolactin receptor (PRLR) variants with prolactinomas.

Hum Mol Genet 2018 Nov 15. Epub 2018 Nov 15.

Academic Endocrine Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 7LJ, UK.

Prolactinomas are the most frequent type of pituitary tumors, which represent 10-20% of all intracranial neoplasms in humans. Prolactinomas develop in mice lacking the prolactin receptor (PRLR), which is a member of the cytokine receptor superfamily that signals via Janus kinase-2-signal transducer and activator of transcription-5 (JAK2-STAT5) or phosphoinositide 3-kinase-Akt (PI3K-Akt) pathways to mediate changes in transcription, differentiation and proliferation. To elucidate the role of the PRLR gene in human prolactinomas, we determined the PRLR sequence in 50 DNA samples (35 leucocyte, 15 tumors) from 46 prolactinoma patients (59% males, 41% females). Read More

View Article
November 2018
2 Reads

Controversies in Breastfeeding.

Authors:
Riccardo Davanzo

Front Pediatr 2018 1;6:278. Epub 2018 Nov 1.

Division of Pediatrics and Neonatology, Department of Mother and Child Health, Ospedale Madonna delle Grazie, Matera, Italy.

When addressing the compatibility of breastfeeding with certain maternal conditions, we need to differentiate between "contraindication" and "obstacle." Failure to distinguish between the two confuses new mothers and their families, and engenders misconceptions about breastfeeding advice by health professionals. Health conditions that may simply impede the initiation and duration of breastfeeding are often wrongly referred to as true contraindications to breastfeed, under the assumption that they might harm the health of the mother and/or that of the nursing infant. Read More

View Article
November 2018
4 Reads

Retrospective analysis of 52 patients with prolactinomas following endoscopic endonasal transsphenoidal surgery.

Medicine (Baltimore) 2018 Nov;97(45):e13198

Department of Neurosurgery, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi.

Background: Prolactinomas affect patients' quality of life and even endanger lives. The study aimed to investigate the effect of the endoscopic endonasal transsphenoidal approach (EETA) on 52 patients with prolactinomas.

Methods: A total of 52 patients with prolactinomas who had previously undergone EETA in the People's Hospital of Xinjiang Uygur Autonomous Region between January 2013 and December 2017 were retrospectively analyzed. Read More

View Article
November 2018
2 Reads

The ERα membrane pool modulates the proliferation of pituitary tumours.

J Endocrinol 2018 Nov 1. Epub 2018 Nov 1.

A Torres, Centro de Microscopía Electrónica, Universidad Nacional de Córdoba, Facultad de Ciencias Médicas, - Consejo Nacional de Investigaciones Científicas Técnicas (CONICET) Instituto de Investigaciones en Ciencias de la Salud, Córdoba, Argentina.

The molecular mechanisms underlying the ERα nuclear/cytoplasmic pool that modulates pituitary cell proliferation have been widely described, but it is still not clear how ERα is targeted to the plasma membrane. The aim of this study was to analyse ERα palmitoylation and the plasma membrane ERα (mERα) pool, and their participation in E2-triggered membrane-initiated signalling in normal and pituitary tumour cell growth. Cell cultures were prepared from anterior pituitaries of female Wistar rats and tumour GH3 cells, and treated with 10nM of estradiol (E2). Read More

View Article
November 2018
4 Reads

Giant Prolactinoma in Men: Clinical Features and Therapeutic Outcomes.

Horm Metab Res 2018 Nov 5;50(11):791-796. Epub 2018 Nov 5.

Department of Endocrinology, Hospital Universitario Ramón y Cajal, Madrid, Spain.

The aim of the study was to evaluate the clinical features and long-term therapeutic outcome of giant prolactinoma (gPRLoma) in men and to compare them with those of a group of male patients with non-gPRL macroprolactinomas (non-gPRLomas). A retrospective and multicenter study of gPRLomas in men diagnosed in a 20-year period was performed. Clinical data and treatment outcome were registered. Read More

View Article
November 2018
9 Reads

[Improvement and effect analysis of a new neuroendoscopic trans-nasal-sphenoidal pituitary tumor resection approach].

Zhonghua Yi Xue Za Zhi 2018 Oct;98(37):3021-3024

Department of Neurosurgery, Center of Prolactinoma, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.

To modify the individual neuroendoscopic surgical approach of pituitary tumors with specific imaging features, and to analyze the clinical outcomes. The clinical data of 116 patients with pituitary tumors who underwent surgical treatment at the pituitary tumor diagnosis and treatment center of Ruijin Hospital from April 2014 to December 2017 were collected, then the resection effects and complication rates of pituitary tumors from three different kinds of transsphenoidal approaches (e.g. Read More

View Article
October 2018
1 Read

MicroRNA-93 mediates cabergoline-resistance by targeting ATG7 in prolactinoma.

J Endocrinol 2018 Sep 1. Epub 2018 Sep 1.

Z Su, Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

To date, the management of dopamine agonist (DA)-resistant prolactinomas remains a major clinical problem. Previously, we determined that miRNA-93 expression increases in DA-resistant prolactinomas; however, the role of miRNA-93 in the DA resistance remains largely unexplored. Hence, this study aimed to investigate the susceptibility of tumor cells to cabergoline (CAB) and the autophagy changes in MMQ and GH3 cells after miRNA-93 overexpression or inhibition. Read More

View Article
September 2018
1 Read

Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.

J Endocrinol Invest 2018 Oct 28. Epub 2018 Oct 28.

Department of Histology and Embryology, Medical School of Sun Yat-sen University, No. 74, Zhongshan Road 2, Guangzhou, 510080, Guangdong, China.

Purpose: Prolactinoma is the most commonly seen secretory tumor of pituitary glands, which accounts for approximately up to 40% of total pituitary adenomas. Due to its high drug resistance, dopamine agonist, such as bromocriptine, has limited effect on the treatment of patients with prolactinoma. Recent discoveries have revealed that multiple miRNAs were involved in regulating drug resistance. Read More

View Article
October 2018
7 Reads

No evidence of adverse fertility and pregnancy outcomes in patients with unrecognized and untreated multiple endocrine neoplasia type 1.

Clin Endocrinol (Oxf) 2018 Oct 28. Epub 2018 Oct 28.

School of Medicine, Department of Diabetes and Endocrinology, Royal Hobart Hospital, University of Tasmania, Hobart, Tasmania.

Objective: Literature concerning the impact of multiple endocrine neoplasia type 1 (MEN 1) on fertility is limited to case reports despite the early onset of endocrinopathies, such as primary hyperparathyroidism and prolactinoma, that may impact fertility. This study describes the impact of unrecognized and untreated MEN 1 on fertility and pregnancy outcomes in a multigenerational cohort of the Tasman 1 MEN 1 kindred.

Methods: All MEN 1 positive (MEN 1 , n = 63) and MEN 1 negative (MEN 1 , n = 75) descendants born between 1825 and 1951 of a common founder. Read More

View Article
October 2018
6 Reads

Management of prolactinoma: a survey of endocrinologists in China.

Endocr Connect 2018 Oct;7(10):1013-1019

Division of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.

Objective To assess the current management of prolactinoma among endocrinologists in China. Methods An online survey of a large sample of endocrinologists was conducted in China. The questionnaire included 21 questions related to controversial issues about the management of prolactinomas. Read More

View Article
October 2018
4 Reads

Coexistent Pituitary Adenoma with Rathke's Cleft Cyst: A Case Series.

J Assoc Physicians India 2018 Mar;66(3):42-46

Professor and Head of Department, Department of Endocrinology, Seth GS Medical College, Mumbai, Maharashtra.

Objectives: Co existent pituitary adenoma and Rathke's cleft cyst (RCC) is a rare entity. Purpose of this study is to describe the clinical presentation, imaging findings, and management of patients with this combination.

Methods: Retrospective review of records from a single tertiary care center for a period of three years [2009-2012]. Read More

View Article
March 2018
7 Reads

Prolactin, prolactin disorders, and dopamine agonists during pregnancy.

Hormones (Athens) 2018 Oct 19. Epub 2018 Oct 19.

Department of Obstetrics and Gynecology, Hadassah University Hospital, PO Box 12000, 91120, Jerusalem, Israel.

Pituitary disorders, and especially prolactinomas, are not common among pregnant women, though they tend to occur during a woman's years of fertility. The majority of prolactinoma patients present with infertility and menstruation dysfunction; however, prolactinomas are associated with potentially significant morbidity if they remain unrecognized and untreated. Herein, we survey the role of prolactin and prolactinomas in pregnancy while also outlining the therapeutic approach to prolactinoma during pregnancy. Read More

View Article
October 2018
1 Read

Nonalcoholic fatty liver disease with prolactin-secreting pituitary adenoma in an adolescent: A case report.

Medicine (Baltimore) 2018 Oct;97(42):e12879

Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Japan.

Rationale: Nonalcoholic fatty liver disease (NAFLD), among the commonest chronic liver disorders in children and adolescents, is considered a reflection of the current obesity epidemic in children and adults. This liver disease has been linked with various metabolic disorders, but not with prolactinoma (PRLoma).

Patient Concerns: A 13-year-old Japanese girl manifested obesity, serum transaminase and γ-glutamyltransferase elevations, and amenorrhea. Read More

View Article
October 2018
1 Read

Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts.

J Cell Mol Med 2018 Dec 18;22(12):6368-6379. Epub 2018 Oct 18.

Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medicine Sciences & Peking Union Medical College, Beijing, China.

Metformin (MET) is a diabetes drug that activates AMP-activated protein kinase (AMPK), and is suggested to have anticancer efficacy. Here, we investigated the role of AMPK signalling in prolactinoma (PRLoma), with particular respect to MET and bromocriptine (BC) as a PRLoma treatment. We analysed AMPK phosphorylation, dopamine D2 receptor (D2R), and oestrogen receptor (ER) expression in both BC-sensitive and -resistant PRLoma samples; effects of the AMPK agonist MET (alone or with BC) on in vitro proliferation and apoptosis, xenograft growth and prolactin (PRL) secretion of BC-sensitive and -resistant cells, and ER expression in xenografts. Read More

View Article
December 2018
1 Read

Evaluation of Hypothalamic-Pituitary-Adrenal Axis by the GHRP2 Test: Comparison With the Insulin Tolerance Test.

J Endocr Soc 2018 Aug 26;2(8):860-869. Epub 2018 Jun 26.

Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.

Context: GH-releasing peptide 2 (GHRP2) stimulates the hypothalamic-pituitary-adrenal axis (HPA) through the GH secretagogue receptor (GHSR) in the hypothalamus, in which ghrelin is a natural ligand. Therefore, the GHRP2 test (GHRP2T) could be used instead of the insulin tolerance test (ITT).

Objective: Can the GHRP2T replace the ITT for evaluation of HPA?

Design: The present retrospective study analyzed the clinical features and laboratory data from 254 patients admitted for evaluation of hypopituitarism who underwent both GHRP2T and ITT. Read More

View Article
August 2018
1 Read

Pituitary Adenoma Apoplexy of the Orbit, Diagnosis, and Management With Presurgical Embolization.

Ophthalmic Plast Reconstr Surg 2018 Nov/Dec;34(6):e196-e197

Johns Hopkins University School of Medicine, Wilmer Eye Institute, Baltimore, Maryland, U.S.A.

Orbital invasion of pituitary adenomas has been previously reported. In this report, the authors describe a 71-year-old female with a prolactinoma that presented with invasion of and apoplexy within the orbit. The patient underwent exenteration, followed by rapid tumor recurrence and growth. Read More

View Article
October 2018
1 Read

Utility of N-Ammonia PET/CT to Detect Pituitary Tissue in Patients with Pituitary Adenomas.

Acad Radiol 2018 Oct 12. Epub 2018 Oct 12.

Department of Neurosurgery and Pituitary Tumor Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Electronic address:

Rationale And Objectives: It is clinically essential, but sometimes challenging, to distinguish pituitary tissue from pituitary adenomas (PAs). It is helpful to avoid damage of pituitary tissue during management. We evaluated the ability of N-ammonia positron emission tomography (PET)/computed tomography (CT) to locate and distinguish pituitary tissue from PAs. Read More

View Article
October 2018
6 Reads

Pasireotide: A potential therapeutic alternative for resistant prolactinoma.

Ann Endocrinol (Paris) 2018 Sep 25. Epub 2018 Sep 25.

Centre de référence maladies rares hypophysaires (HYPO), fédération d'endocrinologie, groupement hospitalier Est, hospices civils de Lyon, 69677 Bron, France; Faculté de médecine Lyon Est, université Lyon 1, 69372 Lyon, France; Inserm U1052, CNRS UMR5286, Cancer Research Centre of Lyon, 69372 Lyon, France. Electronic address:

Context: About 10% of prolactinomas are resistant to dopamine-agonists (DAs). The only alternatives for tumor and prolactin control are surgery or radiotherapy. While studies on first generation somatostatin analogs have shown no efficacy against prolactinomas, no study has been conducted on the new multireceptor-targeted somatostatin receptor ligand pasireotide, which presents high affinity for 5, 3, 2 and 1 receptor subtypes. Read More

View Article
September 2018
1 Read

Endonasal chiasmapexy using autologous cartilage/bone for empty sella syndrome after cabergoline therapy for prolactinoma: A case report.

World Neurosurg 2018 Oct 10. Epub 2018 Oct 10.

Neurosurgery and Department of.

Background: Visual field deterioration caused by secondary empty sella after cabergoline therapy for prolactinoma is a rare event. Chiasmapexy is performed to treat empty sella syndrome. Although various materials have been used for the elevation of the optic chasm, the most appropriate material remains to be established. Read More

View Article
October 2018
2 Reads

DICER1 mutation and pituitary prolactinoma

Endocrinol Diabetes Metab Case Rep 2018 Sep 25;2018. Epub 2018 Sep 25.

Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK

A young woman carrying germline DICER1 mutation was discovered to have a pituitary microprolactinoma when she became amenorrhoic. The mutation was identified as a result of family screening following the early death of the patient’s daughter with ovarian cancer. The patient was in follow-up screening for thyroid disease, and investigations were initiated when she became amenorrhoic. Read More

View Article
September 2018
9 Reads

T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.

Endocrine 2018 Sep 28. Epub 2018 Sep 28.

Department of Endocrinology, CHU Mont-Godinne-Dinant, Université catholique de Louvain, Yvoir, Belgium.

Purpose: Recent work supports the use of T2-weighted MRI intensity as a tool for treatment stratification in acromegaly. Our study aimed to establish if the pattern of T2 intensity could be a predictor of hormonal and/or tumoral response to dopamine agonists (DAs) in prolactinomas.

Methods: This was a retrospective study performed in two academic centers. Read More

View Article
September 2018
5 Reads

Ept7, a quantitative trait locus that controls estrogen-induced pituitary lactotroph hyperplasia in rat, is orthologous to a locus in humans that has been associated with numerous cancer types and common diseases.

PLoS One 2018 27;13(9):e0204727. Epub 2018 Sep 27.

McArdle Laboratory for Cancer Research, Department of Oncology, School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin, United States of America.

Pituitary adenoma is a common intracranial neoplasm that is observed in approximately 10% of unselected individuals at autopsy. Prolactin-producing adenomas, i.e. Read More

View Article
September 2018
7 Reads

Multiple Endocrine Neoplasia Type 1: A Case Report With Review of Imaging Findings.

Ochsner J 2018 ;18(2):170-175

Department of Radiology, Ochsner Clinic Foundation, New Orleans, LA.

Background: Multiple endocrine neoplasia type 1 (MEN1) is a rare, autosomal dominant inherited syndrome caused by mutations in the MEN1 tumor suppressor gene. The diagnosis is defined clinically by the presence of 2 or more primary MEN1 tumors (parathyroid, anterior pituitary, and pancreatic islet). We describe the case of a patient who presented with classic history and imaging findings for MEN1. Read More

View Article
January 2018
2 Reads

Neurosurgical anesthesia for a pregnant woman with macroprolactinoma: A case report.

Medicine (Baltimore) 2018 Sep;97(37):e12360

Department of Anesthesiology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China.

Rationale: Being required to perform neurosurgery on a pregnant woman is rare, but occasionally unavoidable. In these cases, clinical anesthesiologists are confronted with conflicting information and few evidence-based guidelines.

Patient Concerns: Here, we describe the successful anesthetic management of a 24-week pregnant woman with macroprolactinoma who underwent endonasal transsphenoidal resection of pituitary adenoma. Read More

View Article
September 2018
2 Reads

Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up.

Endocrine 2018 Sep 11. Epub 2018 Sep 11.

Department of Endocrinology and Metabolism, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey.

Objective: To assess prospectively the prevalence of impulse control disorders (ICD), psychiatric symptoms, and their clinical correlates in patients with prolactinoma receiving dopamine agonists (DA) in comparison to those with non-functioning pituitary adenomas (NFA) and healthy controls (HC).

Methods: A total of 25 patients with prolactinoma, 31 with NFA, and 32 HCs were included in the study. All patients and controls were screened for the presence of ICDs and other psychiatric disorders using revised version of Minnesota Impulsive Disorders Interview (MIDI-R), Barratt Impulsiveness Scale (BIS-11), Symptom Check List (SCL-90-R) questionnaire and Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI). Read More

View Article
September 2018
13 Reads

Familial Cancer Clustering in Patients with Prolactinoma.

Horm Cancer 2018 Sep 8. Epub 2018 Sep 8.

School of Medicine, University of Belgrade, Dr Subotic 8, Belgrade, 11000, Serbia.

People are at higher risk for malignancy as they get older or have a strong family history of cancer. This study aims to collect family history of cancer in a large cohort of patients with pituitary adenomas (PA) in outpatient clinic from years 2005-2017. Overall, 46. Read More

View Article
September 2018
2 Reads

Pituitary Apoplexy in Long-Term Cabergoline User During Thrombocytopenia Due to Chemotherapy for Chronic Myelocytic Leukemia.

World Neurosurg 2018 Dec 3;120:290-295. Epub 2018 Sep 3.

Department of Neurosurgery, Kurashiki Central Hospital, Okayama, Japan.

Background: Pituitary apoplexy (PA) is a life-threatening syndrome. The usage of a dopamine agonist, such as bromocriptine or cabergoline, is considered a predisposing factor for PA, which commonly occurs 1.5 years within commencement. Read More

View Article
December 2018
4 Reads

Giant Prolactinoma of Young Onset: A Clue to Diagnosis of MEN-1 Syndrome.

Case Rep Endocrinol 2018 14;2018:2875074. Epub 2018 Aug 14.

Department of Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, UK.

Multiple endocrine neoplasia (MEN) type 1 syndrome is an autosomal dominant disorder caused by germline mutations in gene, characterized by tumours in endocrine and nonendocrine organs. Giant prolactinoma is defined as tumours larger than 40mm with very high prolactin secretion. We report two unrelated Sri Lankan patients (8-year-old boy and a 20-year-old female) who presented with giant prolactinomas with mass effects of the tumours. Read More

View Article
August 2018
13 Reads

Dopamine Agonists for Pituitary Adenomas.

Front Endocrinol (Lausanne) 2018 21;9:469. Epub 2018 Aug 21.

Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv-Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Dopamine agonists (DA) are well established as first-line therapy for prolactinomas. These tumors express high levels of dopamine 2 receptors (D2R), leading to the strong efficacy of DA in reducing tumor size and hormonal secretion. Other pituitary tumor subtypes express D2R to varying degrees, leading to an extensive body of research into potential off-label use of DA in non-prolactinoma pituitary tumors. Read More

View Article
August 2018
2 Reads

Atypical giant prolactinoma with frontal lobe manifestations.

BMJ Case Rep 2018 Sep 4;2018. Epub 2018 Sep 4.

Diabetes and Endocrine Department, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

View Article
September 2018
2 Reads

Fulvestrant inhibits the glycolysis of prolactinoma GH3 cells by downregulating IRE1/XBP1 signaling pathway.

Eur Rev Med Pharmacol Sci 2018 Aug;22(16):5364-5370

Department of Neurosurgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, China.

Objective: We aimed to evaluate the effects of fulvestrant on the glycolysis of prolactinoma GH3 cells, and reveal the potential regulatory mechanisms.

Materials And Methods: Prolactinoma cell line GH3 was treated with different concentrations of fulvestrant (0, 0.12, 0. Read More

View Article
August 2018
6 Reads

Beat the giant: case of a giant prolactinoma during pregnancy on cabergoline.

Endocrinol Diabetes Metab Case Rep 2018 23;2018. Epub 2018 Aug 23.

Obesity, Endocrine, and Metabolism Center, King Fahad Medical City, Riyadh, Saudi Arabia.

Giant prolactinomas are a rare entity; during pregnancy, the risk for complications associated with these tumors is higher. Here, we report a case of a young woman who had an invasive, giant prolactinoma post resection with residual disease who became pregnant. This patient was treated with cabergoline to prevent tumor expansion in pregnancy, resulting in the uneventful delivery of a healthy baby boy. Read More

View Article
August 2018
8 Reads

Etiological Profile of Galactorrhoea.

Indian J Endocrinol Metab 2018 Jul-Aug;22(4):489-493

Department of Endocrinology, Vydehi Institute of Medical Sciences and Research Center, Bengaluru, Karnataka, India.

Background: Recent increase in the non-specific use of prokinetics in clinical practice may alter the etiological profile of hyperprolactinemia and galactorrhea. Hence, we have studied the etiological profile of patients presenting with galactorrhea and characteristics of drug-induced galactorrhea.

Materials And Methods: This retrospective study was conducted at a tertiary health care center from South India. Read More

View Article
August 2018
12 Reads

Cabergoline treatment in prolactinoma: amelioration in obstructive and central sleep apneas.

J Postgrad Med 2018 Aug 24. Epub 2018 Aug 24.

Department of Otolaryngology, Head and Neck Surgery, Gulhane Medical School, Ankara, Turkey.

A 44-year-old male patient was admitted to the otolaryngology department with a history of progressive snoring, excessive daytime sleepiness, and reduced libido for the last 6 months. Polysomnography demonstrated the presence of moderate obstructive sleep apnea (OSA) with an apnea-hypopnea index (AHI) of 24.6 events/h, consisting of 77 obstructive and 59 central apneas. Read More

View Article
August 2018
2 Reads

Prolactin-Secreting Lung Adenocarcinoma Metastatic to the Pituitary Mimicking a Prolactinoma: A Case Report.

Neurosurgery 2018 Aug 20. Epub 2018 Aug 20.

Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Background And Importance: Metastasis to the pituitary gland is uncommon in patients with systemic disseminated cancer. Individual articles have reported cases of pituitary metastasis mimicking a prolactinoma, but no case of a prolactin-secreting tumor metastasizing to the pituitary mimicking a prolactinoma has been reported so far.

Clinical Presentation: This article reports a 67-yr-old man with a recent onset of headaches, ophthalmoplegia, hypopituitarism, and hyperprolactinemia who was initially diagnosed with prolactinoma and given bromocriptine in the local hospital. Read More

View Article
August 2018
4 Reads

Multiple endocrine neoplasia type 1 presenting with concurrent insulinoma and prolactinoma in early-adolescence.

Int J Pediatr Endocrinol 2018 6;2018. Epub 2018 Aug 6.

Department of Pediatrics, Johns Hopkins University School of Medicine, 200 N Wolfe St, Rm 3120, Baltimore, MD 21287 USA.

Background: Multiple Endocrine Neoplasia Type 1 (MEN1) is a rare autosomal dominant disease that generally presents with primary hyperparathyroidism. However, initial presentation may vary and continued reevaluation of etiology of symptoms is required for appropriate diagnosis.

Case Presentation: Twelve year old female presented with altered mental status that self-resolved and hypoglycemia. Read More

View Article
August 2018
10 Reads

Medically induced CSF rhinorrhea following treatment of macroprolactinoma: case series and literature review.

Pituitary 2018 Dec;21(6):561-570

Saint Alphonsus Neuroscience Institute - Neurosurgery, Boise, ID, USA.

Purpose: Although several reports have addressed cerebrospinal fluid (CSF) rhinorrhea following dopamine agonist (DA) therapy of macroprolactinomas, further study is warranted for this relatively uncommon entity. Toward this aim, our retrospective series and review of literature further clarifies recommendations in treatment of this rare problem.

Methods: We retrospectively reviewed all macroprolactinoma cases in our hospital for a 15-year period. Read More

View Article
December 2018
9 Reads
2.220 Impact Factor

Gender-affirming hormone therapy and the risk of sex hormone-dependent tumours in transgender individuals-A systematic review.

Clin Endocrinol (Oxf) 2018 Dec 18;89(6):700-711. Epub 2018 Sep 18.

Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria, Australia.

Background: Cancers are a leading cause of death worldwide, and transgender individuals are no exception. The effects of gender-affirming hormone therapy (GAHT) on sex hormone-dependent tumours are unclear. Therefore, this review seeks to determine whether tumour risk in transgender individuals differs from the general population, to guide clinical screening recommendations. Read More

View Article
December 2018
1 Read

Estrogen receptor antagonist fulvestrant inhibits proliferation and promotes apoptosis of prolactinoma cells by regulating the IRE1/XBP1 signaling pathway.

Mol Med Rep 2018 Oct 10;18(4):4037-4041. Epub 2018 Aug 10.

Department of Neurosurgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, P.R. China.

The aim of the present study was to evaluate the effects of an estrogen receptor antagonist, fulvestrant, on proliferation and apoptosis of prolactinoma cells, and to reveal potential regulatory mechanisms. Prolactinoma GH3 cells were treated with 10‑6 mol/l fulvestrant for 2, 4, 8, 12 and 24 h. GH3 cell growth was observed under a microscope and cell viability was detected by MTT assay. Read More

View Article
October 2018
2 Reads

An uncommon cause of osteoporosis.

J Family Med Prim Care 2018 Mar-Apr;7(2):455-457

Department of Endocrinology, Diabetes and Metabolism, Christian Medical College and Hospital, Vellore, Tamil Nadu, India.

Osteoporosis in the younger age group is an important cause of morbidity. Prolactinoma is an uncommon but reversible cause of osteoporosis. The main mechanisms of osteoporosis in prolactinoma are reduced osteoblast activity and hypogonadism. Read More

View Article
August 2018
2 Reads

Macroprolactinomas: longitudinal assessment of biochemical and imaging therapeutic responses.

Endocrine 2018 11 7;62(2):470-476. Epub 2018 Aug 7.

Endocrinology Department, Hospital de Braga, Braga, Portugal.

Purpose: To assess biochemical and imaging therapeutic response rates, when these occur and their predictive factors in patients with macroprolactinomas treated with dopamine agonists (DA).

Methods: Retrospective, longitudinal study of patients with macroprolactinomas treated with DA for ≥12 months.

Outcomes: prolactin normalization, reduction in maximum tumor diameter ≥50% and time until therapeutic responses. Read More

View Article
November 2018
4 Reads

A patient with a germline mutation presenting with an isolated pituitary macroprolactinoma.

Endocrinol Diabetes Metab Case Rep 2018 21;2018. Epub 2018 Jul 21.

Endocrinology, Imperial College Healthcare NHS Trust, London, UK.

Symptomatic pituitary adenomas occur with a prevalence of approximately 0.1% in the general population. It is estimated that 5% of pituitary adenomas occur in a familial setting, either in isolated or syndromic form. Read More

View Article
July 2018
8 Reads

The Third Case of Cabergoline-Associated Valvulopathy: The Value of Routine Cardiovascular Examination for Screening.

J Endocr Soc 2018 Aug 11;2(8):965-969. Epub 2018 Jul 11.

Department of Diabetes and Endocrinology, Princess Alexandra Hospital Brisbane, and Faculty of Medicine, University of Queensland, Brisbane, Australia.

A decade after the alarming association of cabergoline-associated valvulopathy (CAV) in Parkinson disease, only two confirmed cases have occurred in patients with prolactinoma. Routine screening for CAV by echocardiography has not proved to be of diagnostic utility, has several limitations, and is not widely practiced. We have previously highlighted the value of annual cardiovascular examination as a screening tool for CAV in patients with prolactinoma. Read More

View Article
August 2018
2 Reads